Interpretation and utility of drug of abuse immunoassays lessons from laboratory drug testing surveys

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 5, 2010, Pages 735-739

  Melanson, Stacy E F ^a   Baskin, Leland ^b   Magnani, Barbarajean ^c   Kwong, Tai C ^d   Dizon, Annabel ^e   Wu, Alan H B ^f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e Proficiency Testing Division   (United States)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; OXYCODONE;

ARTICLE; HUMAN; IMMUNOASSAY; INFORMATION PROCESSING; LABORATORY; METHODOLOGY; STANDARD; SUBSTANCE ABUSE; URINE;

DATA COLLECTION; HUMANS; IMMUNOASSAY; LABORATORIES; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXYCODONE; SUBSTANCE ABUSE DETECTION;

EID: 77952073545     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Department of Health and Human Services. Drug Abuse Warning Network Web site. http://www.dawninfo.samhsa.gov. Accessed May 28, 2009.
2. Hammett-Stabler CA, Pesce AJ, Cannon DJ. Urine drug screening in the medical setting. Clin Chim Acta. 2002;315(1-2):125-135.
3. Wu AHB, McKay C, Broussard LA, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin Chem. 2003;49(3):357-379.
4. Trescot AM, Boswell MV, Atluri SL et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9(1):1-39.
5. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27(3):260-267.
6. Colbert DL. Drug abuse screening with immunoassays: unexpected crossreactivity and other pitfalls. Br J Biomed Sci. 1994;51(2):136-146.
7. Magnani B. Concentrations of compounds that produce positive results. In: Shaw LM, Kwong TC, Rosano TG, Orsulak PJ, Wolf BA, Magnani B, eds. The Clinical Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation. Washington, DC: AACC Press; 2001:481-498.
8. National Institute of Drug Abuse. The Advance Report: Epidemiological Trends in Drug Abuse. http://www.drugabuse.gov/PDF/CEWG/AdvReport108.pdf. Accessed May 28, 2009.
9. Drug Enforcement Administration. National Forensic Laboratory Information System Midyear Report. http://www.deadiversion.usdoj.gov/nflis/2007-midyear. pdf. Accessed May 28, 2009.
10. Miller JJ, Valdes R. Methods for calculating crossreactivity in immunoassays. J Clin Immunoassay. 1992;15(8):97-107.
11. Marchei E, Pellegrini M, Pichini S, Martin I, Garcia-Algar O, Vall O. Are false-positive phencyclidine immunoassay instant-view multi-test results caused by overdose concentrations of ibuprofen, metamizol, and dextromethorphan? Ther Drug Monit. 2007;29(5):673-671.
12. Asselin WM, Leslie JM. Use of the EMITtox serum tricyclic antidepressant assay for the analysis of urine samples. J Anal Toxicol. 1990;14(3):168-171.
13. Stout PR, Klette KL, Horn CK. Evaluation of ephedrine, pseudoephedrine and phenylpropanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays. J Forensic Sci. 2004;49(1):160-164.